A randomized phase III trial assessing in patients with advanced non-small cell lung cancer not progressing on first line cisplatin-gemcitabine chemotherapy maintenance chemotherapy with gemcitabine or sequential treatment with erlotinib.

Trial Profile

A randomized phase III trial assessing in patients with advanced non-small cell lung cancer not progressing on first line cisplatin-gemcitabine chemotherapy maintenance chemotherapy with gemcitabine or sequential treatment with erlotinib.

Completed
Phase of Trial: Phase III

Latest Information Update: 28 Sep 2012

At a glance

  • Drugs Erlotinib (Primary) ; Gemcitabine (Primary) ; Cisplatin; Pemetrexed
  • Indications Non-small cell lung cancer
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 28 Sep 2012 Results of the cost-utility analyses presented at the 37th Congress of the European Society for Medical Oncology.
    • 04 Sep 2012 Results published in the Journal of Clinical Oncology.
    • 28 Jun 2012 Cost-utility added as a descriptor and PEC added as a therapeutic area
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top